ROTATE
Improving MRD Negativity Rates in Newly Diagnosed Multiple Myeloma Patients: a Response-adaptive Approach of Consolidation With One or Two Bispecific T-cell Engagers Against GPRC5D or BCMA
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 50 patients (estimated)
- Sponsors
- Yale Cancer Center
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, GPRC5D, Minimal Residual Disease (MRD), Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2127
- NCT Identifier
- NCT06993675
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.